IMPAX, Schering-Plough Settles Claritin-D 24-Hour Patent Suit
As part of the agreement, IMPAX Laboratories entered into license agreement with Schering-Plough related to IMPAX's generic version of Claritin-D 24-Hour (Loratadine and Pseudoephedrine Sulfate, 10mg/240mg) Extended Release Tablets.
The agreement resolves all of the outstanding patent litigation between the parties on this product, IMPAX said.
"This case is currently at the summary motion phase and now, with this settlement, we can eliminate any additional expense or delays due to this lawsuit,"...
To view the full article, register now.